Wouter L Lodder1,2, Bernard F A M van der Laan1, Tristram H Lesser3, Samuel C Leong4. 1. Department of Otorhinolaryngology/Head and Neck Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. 2. Department of Otorhinolaryngology/Head and Neck Surgery, Medical Centre Leeuwarden, Leeuwarden, The Netherlands. 3. The Skull Base Unit, Department of Otorhinolaryngology-Head and Neck Surgery, University Hospital Aintree, Liverpool, L9 7AL, UK. 4. The Skull Base Unit, Department of Otorhinolaryngology-Head and Neck Surgery, University Hospital Aintree, Liverpool, L9 7AL, UK. lcheel@doctors.org.uk.
Abstract
OBJECTIVE: To quantify the impact of acoustic neuroma on the quality-of-life (QOL) patients in the United Kingdom. STUDY DESIGN: Online questionnaire survey. PATIENTS: Members of the British Acoustic Neuroma Association received PANQOL questionnaires. RESULTS: Of the 880 BANA members contacted, 397 (45.1%) responded, although only 359 had complete datasets for analysis. Composite QOL scores were as follows: for microsurgery 58 (SD 35), for radiotherapy 56 (SD18), for combination of surgery and radiotherapy 49 (SD 14), and for the observation group 54 (SD 20). No statistical significance with ANOVA (p = 0.532). Mean (SD) composite QOL scores were as follows: for follow-up < 6 52 (SD 18), for follow-up 6-10 55 (SD 20) and follow-up > 10 years 65 (SD 45). Overall, these values were significantly different compared by ANOVA (p < 0.001). Patients with facial paralysis showed no statistical significant differences between the different treatment groups. CONCLUSIONS: Short- (< 6 years) and long-term (> 10 years) QOL outcomes show no significant differences between the different treatment groups.
OBJECTIVE: To quantify the impact of acoustic neuroma on the quality-of-life (QOL) patients in the United Kingdom. STUDY DESIGN: Online questionnaire survey. PATIENTS: Members of the British Acoustic Neuroma Association received PANQOL questionnaires. RESULTS: Of the 880 BANA members contacted, 397 (45.1%) responded, although only 359 had complete datasets for analysis. Composite QOL scores were as follows: for microsurgery 58 (SD 35), for radiotherapy 56 (SD18), for combination of surgery and radiotherapy 49 (SD 14), and for the observation group 54 (SD 20). No statistical significance with ANOVA (p = 0.532). Mean (SD) composite QOL scores were as follows: for follow-up < 6 52 (SD 18), for follow-up 6-10 55 (SD 20) and follow-up > 10 years 65 (SD 45). Overall, these values were significantly different compared by ANOVA (p < 0.001). Patients with facial paralysis showed no statistical significant differences between the different treatment groups. CONCLUSIONS: Short- (< 6 years) and long-term (> 10 years) QOL outcomes show no significant differences between the different treatment groups.
Authors: Matthew L Carlson; Øystein Vesterli Tveiten; Kathleen J Yost; Christine M Lohse; Morten Lund-Johansen; Michael J Link Journal: Otolaryngol Head Neck Surg Date: 2015-06-02 Impact factor: 3.497
Authors: Matthew L Carlson; Oystein Vesterli Tveiten; Colin L Driscoll; Frederik K Goplen; Brian A Neff; Bruce E Pollock; Nicole M Tombers; Marina L Castner; Monica K Finnkirk; Erling Myrseth; Paal-Henning Pedersen; Morten Lund-Johansen; Michael J Link Journal: J Neurosurg Date: 2015-01-02 Impact factor: 5.115
Authors: Bibian M van Leeuwen; Jasmijn M Herruer; Hein Putter; Jeroen C Jansen; Andel G L van der Mey; Adrian A Kaptein Journal: Otol Neurotol Date: 2013-07 Impact factor: 2.311
Authors: Zachary N Robinett; Patrick C Walz; Beth Miles-Markley; Aaron C Moberly; D Bradley Welling Journal: Otolaryngol Head Neck Surg Date: 2014-03-04 Impact factor: 3.497